Armed with Japanese Data, Nichi-Iko Confident of Besting Nippon Kayaku in Remicade Biosimilar Race

Kenji Matsuyama, Senior Operating Officer, Head of Corporate Strategy & Planning Division, Nichi-Iko Nichi-Iko Pharmaceutical is set to join the fray in the Japanese follow-on biologics market by rolling out its first biosimilar, which will be the second Remicade (infliximab)...read more